Top Brand
Our Recommendation
520+ trust this
WHO GMP Certified
520+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
In Noncirrhotic Non-Alcoholic Steatohepatitis Noncirrhotic non-alcoholic steatohepatitis (NASH) is liver inflammation and damage caused by excess fat in the liver. Because of the damage, the liver doesn't work as well as it should. Bilypsa Tablet reduces fat deposition thereby improving its overall functioning. In Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease is a condition in which there is an increased buildup of fat in the liver. It affects people who drink little to no alcohol. Bilypsa Tablet protects the liver and reduces the risk of liver failure. In Diabetic dyslipidemia (high cholesterol in diabetes) Bilypsa Tablet helps in the management of high cholesterol, as well as blood sugar levels in people with type 2 diabetes. It is mainly used in people whose cholesterol levels are not controlled by statin therapy alone. By controlling high cholesterol levels, Bilypsa Tablet helps reduce the risk of heart diseases.
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Bilypsa Tablet can be taken it with or without food, although it's advisable to take it consistently at the same time.
Bilypsa Tablet contains Saroglitazar, a dual action peroxisome proliferator-activated receptor (PPAR) inhibitor that aids in the management of high cholesterol, especially triglycerides, as well as blood sugar levels in people with type 2 diabetes. It acts by a unique mechanism in which it reduces the synthesis and secretion of triglycerides (a type of lipid or cholesterol in blood). It also improves insulin sensitivity of the body for better utilization of the existing insulin and hence lowers the blood sugar levels.
Unsafe: Avoid consuming alcohol with Bilypsa Tablet 10 Tablet as it is deemed unsafe.
Seek medical advice from your doctor: Bilypsa Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Caution Advised: Bilypsa Tablet should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
SAFE - Bilypsa Tablet does not usually affect your ability to drive.
Seek medical advice from your doctor: There is limited information available on the use of Bilypsa Tablet in patients with kidney disease. Doctor consultation is advised.
Seek medical advice from your doctor: There is limited information available on the use of Bilypsa Tablet in patients with liver disease. Doctor consultation is advised.
If you forget a dose of Bilypsa Tablet 10 Tablet take it as soon as you remember. But if your next dose is near, skip the missed one and continue with your regular schedule. Avoid doubling up on doses to compensate for the missed one.
Zydus Tower, Satellite Cross Roads,Ahmedabad 380015 Gujarat, India.
Saroglitazar. Ahmedabad, India: Cadila Healthcare Limited; 2013 (13 Mar. 2019)
Rajesh NA, Drishya L, Ambati MMR, Narayanan AL, Alex M, R KK, Abraham JJ, Vijayakumar TM. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):61-67 (06 Aug. 2023)
Padole P, Arora A, Sharma P, et al. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):435-439 (06 Aug. 2023)
Padole P, Arora A, Sharma P, et al. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):435-439 (06 Aug. 2023)
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.